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a b s t r a c t
Background and objective: The point prevalence survey was conducted as part of the Antibiotic
Resistance and Prescribing in European Children (ARPEC) Project. The study aimed at
analyzing pediatric and neonatal antimicrobial prescribing patterns in Latvian hospitals,
to identify targets for quality improvement.
Materials and methods: A one day cross-sectional point prevalence survey on antibiotic use in
hospitalized children was conducted in November 2012 in 10 Latvian hospitals, using a
previously validated and standardized method. The survey included all inpatient pediatric
and neonatal beds and identified all children receiving an antimicrobial treatment on the
day of survey.
Results: Overall 549 patients were included in the study; 167 (39%) patients admitted to
pediatric wards and 25 (21%) patients admitted to neonatal wards received at least one
antimicrobial. Pediatric top three antibiotic groups were third-generation cephalosporins
(55 prescriptions, 28%), extended spectrum penicillins (n = 32, 16%) and first-generation
cephalosporins (n = 26, 13%). Eleven pediatric patients (85%) received surgical prophylaxis
more than 1 day; 143 pediatric patients (86%) received antibiotics intravenously. Lower
respiratory tract infections were the most common indications for antibiotic use both in
pediatric (n = 60, 35.9%) and neonatal patients (n = 9, 36%). The most used antibiotics for
neonatal patients were benzylpenicillin (n = 12, 32%), and gentamicin (n = 9, 24%).
Conclusions: We identified a few problematic areas, which need improvement: the high use
of third-generation cephalosporins for pediatric patients, prolonged surgical prophylaxis,
predominant use of parenteral antibiotics and an urgent need for local antibiotic guidelines.
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Antibiotics are among the most common medicines given to
children [1,2]. According to some studies, 60% of the children
receive at least one antibiotic during their hospital stay [3].
There is been a lot of discussion about the rational use of
antibiotics because wrongly used they can become a risk factor
for the development of resistant bacteria and extra costs for
both hospitals and patients [4–6]. There are limited reliable
data on antibiotic use in neonates and children in hospitals but
without such information it is difficult to ‘‘develop strategies
for the prevention of infections and the containment of
resistant pathogens’’ [7] and to improve antibiotic prescribing
practices. According to Zarb et al. one of the best ways to
monitor antibiotic prescribing would be through monitoring
electronic prescribing in hospitals that is still not available in
many hospitals in Europe (including Latvian hospitals). The
alternative is point prevalence surveys (PPSs) that is also a
useful tool for this purpose and allows identifying priorities for
quality improvement [8]. There are well-established surveil-
lance methodologies developed by The European Surveillance
of Antimicrobial Consumption (ESAC) Project but these PPSs
have focused mainly on adults [9]. PPSs have been used in
hospitals not only at the European level but also undertaken at
the national and individual hospital level [10,11]. There are
some studies on antibiotic use in pediatric population using
PPSs [12] but methodology was adopted from adult PPSs and it
was not specifically designed for children. This study was a
part of the ‘‘Antibiotic Resistance and Prescribing in European
Children’’ (ARPEC) project. The aim of this particular study was
to analyze the use of antibiotics among children at hospitals in
Latvia to identify targets for quality improvement.
2. Materials and methods
A one-day cross-sectional point prevalence survey (PPS) was
conducted at those hospitals in Latvia with pediatric and
neonatal wards which had agreed to participate in the study. A
previously validated and standardized ARPEC methodology was
used [13–15]. Each hospital was registered in the ARPEC
database providing the name, geographic location and type of
hospital (primary, secondary, tertiary level and specialized
hospital and teaching versus nonteaching hospital). Seven
major pediatric ward types (general pediatric medicine, four
types of specialized pediatric medicine wards, pediatric surgery
and pediatric intensive care unit (PICU)) and four major neonatal
wards were defined (three levels of neonatal intensive care units
(NICUs) and a general neonatal medical ward) [14,15]. The
survey was undertaken during November 2012. The survey days
were following: hospital No. 1296, November 30; hospital No.
1312, November 28; hospital No. 1288, November 14 and 20;
hospital No. 1291, November 12, 19, 20, and 28; hospital No. 1937,
November 30; hospital No. 1324, November 1, 5, 6, 7, 12, 13, 15, 21,
22, 27, and 29; hospital No. 1281, November 27; hospital No. 1323,
November 22; hospital No. 1311, November 27 and 29; and
hospital No. 1098, November 14. In this study, all neonates and
children who were younger than 18 years (from 0 days of life till
17 years 11 month 29 days) and who were present at 8 am on theday of survey (and present since midnight at least) were
included. Detailed data were recorded only for patients with
active antimicrobial prescriptions at 8 am on the day of survey.
Prescriptions that became active after 8 am on the day of the
survey were excluded. Day-case patients, out-patients, emer-
gency admissions after midnight and patients in psychiatry
clinics were excluded. Children younger than 18 years admitted
on an adult ward were excluded. Also adults older than 18 years
admitted on a pediatric ward together with their child were
excluded from the survey. Pediatric surgical wards were not
audited on a Monday in order to gather information about
prophylaxis during the previous 24 h (duration of prophylaxis
was either 1 dose, 1 day, or >1 day). None of wards were audited
on holidays and weekend days. The actual data collection was
performed using paper forms: a department form, a pediatric
and a NICU form [14,15]. The following data were collected: the
patients' age, gender, weight, antimicrobial agent (ATC classes
J01, J02, J05, J04A, A07AA, D01BA, P01AB), dose per administra-
tion, number of doses per day, route of administration,
underlying diagnosis, anatomical site of infection or target for
prophylaxis according to the list of provided reasons for
treatment and the indication for therapy (community acquired
versus hospital acquired infection or prophylaxis) [14,15]. The
reason for the treatment for pediatric patients was divided into
twenty one category, e.g., ‘‘Treatment for surgical disease:
proven or suspected infection, e.g., peritonitis, appendicitis,
abscess, epididymitis, any case of acute abdominal problem
admitted under the surgical team, mediastinitis, etc.’’, ‘‘Sepsis
(includes cases of suspected sepsis syndrome or presumed
bacteremia/septicemia), etc.’’ [14]. The reason for the treatment
for neonatal patients was divided into eighteen categories [15].
For each antimicrobial it was allowed to select only one
category. Underlying diagnosis had to be completed in the case
of a chronic pre-existing disease. If choices had to be made,
those underlying diagnoses related to hospital admission and/
or the antibiotic treatment were taken. Underlying diagnoses
groups for pediatric patients were divided into 14 subgroups and
it was allowed to select a maximum of three diagnoses out of
fourteen categories. For neonatal patients there were also 14
subgroups of underlying diagnoses and it was allowed to select a
maximum of three diagnoses out of 14 categories. As denomi-
nator data, the number of admitted patients and the number of
total available beds in each department was used. Six routes of
administration had to be entered: parenteral oral, rectal,
inhalation, intramuscular, intrathecal and intraperitoneal.
Topical use applied on ‘‘skin’’, ‘‘oral’’ topical administration
(e.g., oral gel) was excluded. Targeted treatment was based upon
microbiological culture and/or sensitivity testing, the action of
the remedies given are directed against the cause of the disease
(e.g., positive blood or sputum culture). Besides data needed for
the ARPEC protocol additional information was collected, i.e.,
whether or not patient received intravenous antibiotics more
than 48 h on the day of the PPS and was there a reason for this
written down in medical records. After data collection on wards
and hospitals, participants sent that information to the local
country administrator who used the ARPEC-webPPS program, a
web-based application for data-entry and reporting as designed
by the Laboratory of Medical Microbiology of the University of
Antwerp, Belgium (http://app.esac.ua.ac.be/arpec_webpps/).


















































































































































































































































































































































































































































































































































m e d i c i n a 5 0 ( 2 0 1 4 ) 1 7 5 – 1 8 1 177Data entry was validated using the online validation procedure
which helped to discover errors or provided warnings (e.g.,
departments without entered patients' data). Descriptive
statistics (SPSS 20) was used to characterize pediatric patients.
Ethics approval was obtained from Riga Stradins University
Ethics Committee and hospitals were also individually respon-
sible for ascertaining the need for local ethical approval.
Overall, in Latvia 10 hospitals participated in this PPS. Three
were tertiary-level hospitals, five were regional hospitals, and
two were local hospitals. Of them, two were children hospitals
and eight adult hospitals with pediatric departments. Nine
hospitals surveyed all eligible wards within the hospital; one
hospital surveyed only neonatal wards. Two children hospitals
accounted for 476 pediatric and neonatal beds (62%). There
was observed a wide range of total number of beds: from 10 to
375 (Table 1). Pediatric surgery wards were in three hospitals,
one hospital had pediatric surgical beds within the general
medical ward. Five hospitals had one or more NICUs and
among them large neonatal units – NICU level three were in
three hospitals.
3. Results
Table 2 shows the demographic data of patients under
antibiotic treatment and prophylaxis. Lower respiratory tract
infections (LRTI) were the most common indications for
antibiotic use both in pediatric and neonatal patients (Table 3).
Top three antibiotics for the LRTI treatment in pediatric
patients were ceftriaxone (n = 20 prescriptions, 31%), amoxi-
cillin (n = 13, 20%), and clarithromycin (n = 7, 11%). Six pediatric
patients had two diagnoses as a reason for antibiotic use.
Twelve neonatal patients (48%) and 29 pediatric patients (17%)
received more than one antimicrobial. There were one
zidovudine and seven fluconazole prescriptions of 243
antimicrobial prescriptions. The rest of prescribed antimicro-
bials belonged to J01 group antimicrobials. Patients admitted
to pediatric wards received 21 different antibiotic (J01 group),
and patients admitted to neonatal wards, 13 different
antibiotics. Eight antibiotics accounted for 75% of all antibiotic
use in pediatric patients and five antibiotics in neonatal
patients. Antibiotic classes used for the treatment and
prophylaxis of infection are shown in Table 4. Top five
antibiotics for pediatric patients were ceftriaxone (41 pre-
scriptions, 21%), cefazolin (n = 24, 12%), amoxicillin (n = 22,
11%), cefuroxime (n = 18, 9%), and benzylpenicillin (n = 14, 7%).
Most used antibiotics for neonatal patients were benzylpeni-
cillin (n = 12, 32%) and gentamicin (n = 9, 24%). In total, there
were 15 patients receiving antimicrobial surgical prophylaxis;
13 (87%) received prophylaxis for more than 1 day. The most
used antibiotics for surgical pediatric patients were ceftriax-
one (n = 7, 26%) and metronidazole (n = 4, 15%), cefazolin (n = 4,
15%), and cefuroxime (n = 4, 15%). In three cases, metronida-
zole was used in combination with ampicillin, amoxicillin or
ceftriaxone, ceftriaxone was also used in combination with
oxacillin, cefuroxime was used in combination with gentami-
cin and benzylpenicillin with clindamycin. In total, 143 (86%) of
the pediatric patients received antibiotics intravenously for
both treatment and prophylaxis, and 91 (64%) of them, more
than 48 h.
Table 2 – Demographic data of patients under antibiotic treatment.
Patients' characteristics Total No. of patients under antibiotic treatment Male Female
N = 192 (%) N = 110 (%) N = 82 (%)
Admitted on neonatal wards 25 (13) 17 (68) 8 (32)
Admitted on pediatric wards 167 (87) 93 (56) 74 (44)
Age (months)
Mean  SE 60  5.1 84  7.0 42  7.1
Mode 24 204 36
Skewness 0.564 0.268 1.012
Kurtosis –1.015 1.249 0.201
Age range
<29 days 23 (12) 15 8
>29 days ≤ 1 year 28 (14) 16 12
>1 year ≤ 5 years 51 (27) 21 30
>5 years ≤ 12 years 53 (28) 33 20
>12 < 18 years 37 (19) 25 12
Table 3 – Reasons for the antimicrobial use in pediatric and neonatal patients.
Diagnosis Patients admitted to pediatric wards Patients admitted to neonatal wards
N = 173 (%) N = 25 (%)
Lower respiratory tract infections 60 (34.7) 9 (36)
Upper respiratory tract infections 24 (13.9) 0
Prophylaxis for surgical disease 14 (8.1) 1 (4)
Prophylaxis for medical problems 14 (8.1) 0
Acute otitis media 11 (6.4) 0
Urinary tract infections 10 (5.8) 0
Other 9 (5.2) 1 (4)
Lymphadenitis 6 (3.5) 0
Surgical treatment 7 (4.0) 0
Febrile neutropenia/fever in oncologic patients 4 (2.3) 0
Skin/soft tissue infections 6 (3.4) 0
Sepsis 4 (2.3) 5 (20)
Joint/bone infections 4 (2.3) 0
Prophylaxis for maternal risk factors 0 5 (20)
Prophylaxis for newborn risk factors 0 4 (16)
Table 4 – Antibiotic classes used for the treatment and prophylaxis of infection.
Antibiotic classes Prescriptions for pediatric patients Prescriptions for neonatal patients
N (%) N (%)
Third-generation cephalosporins (J01DD) 55 (27.9) 4 (10.5)
Penicillins with extended spectrum (J01CA) 32 (16.2) 6 (15.8)
First-generation cephalosporins (J01DB) 26 (13.2) 0
Second-generation cephalosporins (J01DC) 18 (9.1) 0
Beta-lactamase sensitive penicillins (J01CE) 14 (7.1) 12 (31.6)
Combinations of sulfonamides and
trimethoprim, including derivatives (J01EE)
13 (6.6) 0
Macrolides (J01FA) 9 (4.6) 0
Other aminoglycosides (J01GB) 9 (4.6) 11 (28.9)
Beta-lactamase resistant penicillins (J01CF) 5 (2.5) 0
Lincosamides (J01FF) 5 (2.5) 0
Glycopeptide antibacterials (J01XA) 2 (1.0) 0
Comb. of penicillins, incl. beta-lactamase
inhibitors (J01CR)
1 (0.5) 0
Carbapenems (J01DH) 1 (0.5) 2 (5.2)
Other 7 (3.6) 3 (3.9)
m e d i c i n a 5 0 ( 2 0 1 4 ) 1 7 5 – 1 8 11784. Discussion
This study provides an analysis of antibiotic use in hospital-
ized pediatric and neonatal patients. The study is importantbecause the use of antibiotics in Latvia according to some
studies is the highest among the European countries [16] and it
is important to analyze reasons behind such high usage of
antibiotics. The study indicates several problematic areas: first
of all, the high use of the third-generation cephalosporins in
m e d i c i n a 5 0 ( 2 0 1 4 ) 1 7 5 – 1 8 1 179pediatric population and especially ceftriaxone that was the
top one antibiotic used in pediatric patient group. In November
2011 the PPS was done in four hospitals (two of them
University hospitals, one regional and one local hospital)
and results were almost similar with last November results, i.
e., pediatric top three antibiotic groups were penicillins with
extended spectrum (n = 39, 40%), the third generation cepha-
losporins (n = 38, 23%), and combinations of sulfonamides and
trimethoprim, incl. derivatives (n = 22, 13%) – the last group
was due to a high number of oncohematology patients who
received co-trimoxazole for medical prophylaxis. Top three
antibiotics for pediatric patients were amoxicillin (n = 23; 14%),
co-trimoxazole (n = 22; 13%), and ceftriaxone (n = 21; 13%). In
May 2012 the PPS was done in four hospitals (two of them
University hospitals, two regional) and top three antibiotic
groups were the third-generation cephalosporins (n = 37, 25%),
penicillins with extended spectrum (n = 31, 21%) and the
second-generation cephalosporins (n = 21, 14%). Top three
antibiotics for pediatric patients were ceftriaxone and cefur-
oxime both (n = 21, 14%) and amoxicillin (n = 20, 13%). These
results show that in all PPS the third-generation cephalospor-
ins were among the mostly used antibiotic groups for pediatric
patients and ceftriaxone was among top three antibiotics in
this patient group. The use of the third-generation cephalos-
porins can lead to the increase of resistant bacterial strains
and should be reduced as a result [17,18]. Some European
countries have reported high increase of the third-generation
cephalosporin-resistant Escherichia coli in their hospital wards
[19]. At the same time some countries such as UK have
succeeded in decreasing of the use of the third-generation
cephalosporins with both publications from the Department of
Health recommending good antimicrobial stewardship, e.g.,
the ‘‘Start Smart then Focus’’ approach [20] and a policy of
restricting cephalosporin prescription and this approach
helped to decrease the use of cephalosporins, for example,
in the Children Hospital in Birmingham [21]. Currently there
are almost no local and also national recommendations for
antibiotic use in hospitals except one University Hospital with
a maternity ward that has local recommendations for adults
and the University Childrens' Hospital that has local recom-
mendations for bronchiolitis, epiglottitis, croup and commu-
nity acquired pneumonia treatment. This situation indicates
an urgent need for recommendations both on national and
local (hospital) level.
Another problematic area is the high use of intravenous
antibiotics. A total of 143 pediatric patients (86%) received
intravenous antibiotics, and 91 (64%), for more than 48 h; 107
patients (85%) received antibiotics intravenously in May 2012
and 112 patients (74%) in November 2011. In this study, we did
not evaluate the appropriateness of the route of therapy or the
initial diagnosis. One explanation of such high use of intrave-
nous antibiotics could be due to social acceptance that
intravenous antibiotics are ‘‘stronger’’ than oral antibiotics in
treating an infection during hospital stay. Some antibiotics (e.g.,
aminoglycosides) are not available in oral form although
sometimes have off-label oral use [22]. Alternatively, some oral
antibiotics are not available on the Latvian market, e.g.,
flucloxacillin and penicillin Whilst some infections (e.g., central
nervous system infections) or patients groups (e.g., neonates)
require parenteral use there are other patient groups(e.g., children, adolescent) and/or diagnoses where the dispro-
portionately high use of intravenous antibiotics should be
reduced at hospitals in Latvia. In some situations (e.g.,
community acquired pneumonia or some cases of acute
pyelonephritis), switch to oral antibiotics allow reducing the
stay at the hospital and has potential benefits because can
decrease the risk of needle-borne infections, need for referral or
admission, administration costs, and family-related costs
[23–25]. Our results are similar with the study done in pediatric
antimicrobialprescribingin32hospitalsof21Europeancountries
where parenteral route was more commonly used than the oral
route for both prophylactic and therapeutic indications [12].
Antibiotic prophylaxis for surgical patients was not focused
on this study. However, further analysis would be beneficial in
the choice of agents, if prophylaxis is appropriately prescribed
and especially duration of treatment. Surgical prophylaxis in
general and unnecessary prolonged prophylaxis (>1 day) in
particular are areas were serious improvements are needed.
Although there were a small number of patients receiving a
surgical prophylaxis in our study, the tendency was that the
duration of the surgical prophylaxis appeared to be longer than
recommended in a high proportion of the cases: 11 patients of
13 received prophylaxis longer than one day. These findings
are similar with results of other studies [12,26–28]. Some of
studies show that many children may not receive antibiotics
were proven benefit and could receive antibiotics when there
is no clear indication for it [29]. The appropriate use of
antibiotics could lead to essential saving not only for the
hospital and patient but also for the health care system [30]
and can help to decrease the incidence of the surgical site
infection and hospital related costs. At the same time overuse
of antibiotics can lead to the emergence or resistant micro-
organisms [13].
The strength of this study is that all hospitals in Latvia used
the same standardized protocol that was also used in hospitals
in other countries and was tested in two ARPEC pilot studies in
2011 and also in two local pilot studies in four hospitals in
Latvia in November 2011 and in May 2012. One common
method used in all those studies allows comparing data not
only at the country level, but also among the institutions from
different countries. PPS are not expensive, but at the same
time efficient method that allows to identify antibiotic
prescribing trends and areas for improvement. Such a
methodology was chosen as a study design for the ARPEC
study of antibiotic prescribing analysis in pediatric and
neonatal patients (both authors of this article participated in
this ARPEC pilot study) [13]. There are PPS conducted in
hospitals in Latvia focusing on adult patient [11], but for the
first time a PPS was conducted only in so many pediatric and
neonatal wards and analyzed separately from adult patients.
Limitations of this study are associated with the study
design – a cross sectional design allows capturing only
particular numbers of patients. We have to analyze all results
bearing in mind that they may represent only situation in the
particular time period and patients with individual conditions
[13]. In some hospitals only few patients received antimicro-
bial treatment. This was a reason why hospitals' results were
not compared, but only general tendencies were analyzed.
Nevertheless, these results are important because children are
not small adults and we need more information about the use
m e d i c i n a 5 0 ( 2 0 1 4 ) 1 7 5 – 1 8 1180of medications, e.g., antibiotics in pediatric population in order
to provide better care for them. Participation in the survey was
voluntary and none of participants was paid for it. Invitations
were sent to all hospitals in Latvia with pediatric and/or
neonatal wards. Some hospitals did not respond to several
invitation letters or declined participation. It is the main
reason why this study does not contain information, for
example, about tuberculosis treatment in pediatric popula-
tion: tuberculosis is treated in a specialized clinic in one of the
adult University hospitals which also has a pediatric ward. At
the same time the University Children's Hospital participated
in the survey and those specialists from hospitals who
participated were very motivated and interested in the survey
and its results. The PPS as a surveillance tool is the first step in
auditing the antimicrobial use in hospitals and allows
identification of priorities for quality improvement what
was the main aim of this study.
5. Conclusions
We identified few problematic areas, which need improve-
ment: the high use of third-generation cephalosporins for
pediatric patients, prolonged surgical prophylaxis, predomi-
nant use of parenteral antibiotics and an urgent need for local
antibiotic guidelines.
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